Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
Editorials & Other Articles
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
CNN: FDA approves standalone use of J&J's ketamine-derived depression treatment
CNN - FDA approves standalone use of J&’s ketamine-derived depression treatment
By Reuters
Published 7:11 PM EST, Tue January 21, 2025
(Reuters) — The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.
The ketamine-derived drug was first approved in 2019 to be used in combination with antidepressants, and later for patients experiencing suicidal thoughts or actions.
“Now that it is also available as a monotherapy, healthcare providers have the freedom to further personalize treatment plans based on individual needs,” Gregory Mattingly, founding partner of St. Charles Psychiatric Associates, said in a statement.
Spravato bought in sales of $780 million for the first nine months of 2024.
MDD is one of the most common mental health disorders in the U.S., according to the National Institutes of Health. About 21 million U.S. adults in 2021 experienced at least one depressive episodes, latest government data shows.
/snip
By Reuters
Published 7:11 PM EST, Tue January 21, 2025
(Reuters) — The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.
The ketamine-derived drug was first approved in 2019 to be used in combination with antidepressants, and later for patients experiencing suicidal thoughts or actions.
“Now that it is also available as a monotherapy, healthcare providers have the freedom to further personalize treatment plans based on individual needs,” Gregory Mattingly, founding partner of St. Charles Psychiatric Associates, said in a statement.
Spravato bought in sales of $780 million for the first nine months of 2024.
MDD is one of the most common mental health disorders in the U.S., according to the National Institutes of Health. About 21 million U.S. adults in 2021 experienced at least one depressive episodes, latest government data shows.
/snip